New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI
September 23, 2024
September 23, 2024
New Treatment Insights into Switching to UZEDY® from Perseris®
September 23, 2024
September 23, 2024
Reporting of the 2024 Annual General Meeting
September 13, 2024
September 13, 2024
Presentation at the H.C. Wainwright 26th Annual Global Investment Conference (New York, September 9 to 11)
September 5, 2024
September 5, 2024
Olanzapine LAI: No PDSS Observed After Completion of c.99% of the Targeted Injections for Submission
September 5, 2024
September 5, 2024
Progress in the Development of the Products Portfolio and the R&D Pipeline
September 3, 2024
September 3, 2024
Participation terms in the Combined General Meeting
August 26, 2024
August 26, 2024
Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine LAI and UZEDY® commercial progress
July 31, 2024
July 31, 2024
Medincell to Present Data Showing Enhanced Potential of Tumor-Targeting Monoclonal Antibody in Melanoma Using BEPO® Technology at he CRS Annual Meeting
July 1, 2024
July 1, 2024
H.C. Wainwright & Co. Initiates MedinCell’s Coverage with a “Buy” Recommendation
